DaShenLin Pharmaceutical Group (603233) Fundamentals 2026 — P/E 16.6x, Revenue Analysis | SniperIQ
DaShenLin Pharmaceutical Group (603233) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥21.4B, trading at ¥18.76 on the SHH. This SniperIQ fundamentals page covers DaShenLin Pharmaceutical Group's valuation (P/E 16.6x, P/B 2.7x), profitability (net margin 4.7%), revenue (¥27.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is DaShenLin Pharmaceutical Group's market cap?
DaShenLin Pharmaceutical Group (603233) has a market capitalization of approximately ¥21.4B, trading at ¥18.76 on the SHH. Market cap moves with the live share price.
What is DaShenLin Pharmaceutical Group's P/E ratio?
DaShenLin Pharmaceutical Group's trailing twelve-month P/E ratio is 16.6x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is DaShenLin Pharmaceutical Group?
DaShenLin Pharmaceutical Group runs a net profit margin of 4.7%, a gross margin of 34.6%, and an operating margin of 7.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does DaShenLin Pharmaceutical Group generate?
DaShenLin Pharmaceutical Group reported revenue of ¥27.5B for fiscal year 2025, with net income of ¥1.2B and earnings per share (EPS) of 1.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does DaShenLin Pharmaceutical Group pay a dividend?
DaShenLin Pharmaceutical Group offers a trailing dividend yield of about 4.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is DaShenLin Pharmaceutical Group financially healthy?
DaShenLin Pharmaceutical Group carries a debt-to-equity ratio of 0.33x and a current ratio of 0.93x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is DaShenLin Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For DaShenLin Pharmaceutical Group (603233) the key facts are: market cap ¥21.4B, P/E 16.6x, revenue ¥27.5B, 52-week range 14.39-21.78. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track DaShenLin Pharmaceutical Group's full fundamentals live
Get DaShenLin Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.